Diffuse non-Hodgkin's lymphoma (disorder)
REMoDL-A- A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma with Acalabrutinib
Year Started: 2021
The REMoDL-A clinical trial evaluates the addition of acalabrutinib to standard of care therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients with previously untreated CD20 positive Diffuse Large B-Cell Lymphoma (DLBCL). As part of the study, original diagnostic FFPE tumour blocks are collected for gene expression profiling and central pathology review using IHC and FISH analysis. Tissue microarray blocks may also be produced if there is sufficient tissue left in the diagnostic FFPE tumour block. ETDA blood samples are collected at baseline before administration of any study drugs and ctDNA blood samples are also collected at 8 different timepoints throughout the study (at baseline, during trial treatment and during follow-up).
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- Outside EU access restriction
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Imaging data | > 6 months |
| Pathology records | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
| Donor Ethnicity | > 6 months |
Male
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% |
Local recurrence of malignant tumor of urinary bladder (disorder)
BL-13
Year Started: 2019
A randomised phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Freezer temperature logs | > 6 months |
| Genomic datasets | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
| Psychological data | > 6 months |
| Donor Ethnicity | > 6 months |
Female
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Urine | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| cDNA/mRNA | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Urine | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% |
Local recurrence of malignant tumor of lung (disorder)
iDx-Lung
Year Started: 2021
Prospective collection of samples from a cohort at high risk of developing lung cancer
- Access:
- Closed to access
- Type:
- Cohort
- Status:
- In progress
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Freezer temperature logs | > 6 months |
| Genomic datasets | > 6 months |
| Donor Ethnicity | > 6 months |
Female
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Nasal washing | -60°C to -85°C | Not applicable | 75% -99% | ||
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Nasal washing | -60°C to -85°C | Not applicable | 75% -99% | ||
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% |
Mesothelioma (malignant, clinical disorder) (disorder)
NERO
Year Started: 2022
Multicentre, 2 arm, open-label UK randomised phase II trial in Mesothelioma patients with any histological subtype and any site, who have previously received an approved systemic therapy containing platinum .
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Freezer temperature logs | > 6 months |
| Genomic datasets | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
| Donor Ethnicity | > 6 months |
Female
Adult (> 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | -60°C to -85°C | Not applicable | 75% -99% | ||
| Serum | -60°C to -85°C | Not applicable | 75% -99% | ||
| Buffy coat | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Local recurrence of malignant tumor of urinary bladder (disorder)
AURORA
Year Started: 2022
Atezolizumab in patients with urinary tract squamous cell carcinoma: a single arm, open label, multicentre, phase II clinical trial
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Clinical records | > 6 months |
| Followup records | > 6 months |
| Freezer temperature logs | > 6 months |
| Genomic datasets | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
| Psychological data | > 6 months |
| Donor Ethnicity | > 6 months |
Female
Adult (> 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% | ||
| Tissue specimen | RT | Not applicable | 75% -99% |
Male
Adult (> 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | RT | Not applicable | 75% -99% | ||
| Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | Not applicable | 75% -99% | ||
| Whole blood | -60°C to -85°C | Not applicable | 75% -99% | ||
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |